Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
0.3584
+0.0019 (0.53%)
At close: Jan 22, 2026, 4:00 PM EST
0.3629
+0.0045 (1.26%)
Pre-market: Jan 23, 2026, 8:11 AM EST
Incannex Healthcare Revenue
Incannex Healthcare had revenue of $12.00K in the twelve months ending September 30, 2025, down -86.05% year-over-year. In the fiscal year ending June 30, 2025, Incannex Healthcare had annual revenue of $86.00K with 616.67% growth.
Revenue (ttm)
$12.00K
Revenue Growth
-86.05%
P/S Ratio
10,340.60
Revenue / Employee
$1,000
Employees
12
Market Cap
124.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 86.00K | 74.00K | 616.67% |
| Jun 30, 2024 | 12.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 539.05K | -883.65K | -62.11% |
| Jun 30, 2021 | 1.42M | 1.01M | 240.67% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurora Cannabis | 263.57M |
| Organigram Global | 186.08M |
| Assertio Holdings | 137.35M |
| Anika Therapeutics | 112.81M |
| InterCure | 72.16M |
| Journey Medical | 59.40M |
| Cumberland Pharmaceuticals | 41.28M |
| Alpha Teknova | 39.80M |
IXHL News
- 1 day ago - Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program - GlobeNewsWire
- 8 days ago - Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards - GlobeNewsWire
- 9 days ago - Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 - GlobeNewsWire
- 7 weeks ago - Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) - GlobeNewsWire
- 2 months ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026 - Newsfile Corp
- 3 months ago - Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus - GlobeNewsWire
- 3 months ago - Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 5 months ago - Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder - GlobeNewsWire